Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
invasive candidiasis
MeSH D058365 - invasive candidiasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D002177:
Candidiasis
29 Companies
7 Drugs
$
Success rate
D000072742:
Invasive fungal infections
0 Companies
0 Drugs
Success rate
D058365:
Invasive candidiasis
1 Company
1 Drug
$
Success rate
D058387:
Candidemia
22 Companies
4 Drugs
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Mundipharma
Rezafungin
Rezzayo
2032-03-02
2023-03-22
Clinical Trials
Historical Success Rate
Phase 1
100
%
1/1
Phase 2
83
%
5/6
Phase 3
45
%
5/11
Approved:
0
Overall Success rate:
38%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Mundipharma
Rezafungin
,
Sodium chloride
,
Microcrystalline cellulose
,
Cotrimoxazole
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use